- Home
- CHRS vs AFCG Comparison
CHRS vs AFCG Comparison
Compare CHRS & AFCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- AFCG
- Stock Information
- Founded
- CHRS 2010
- AFCG 2020
- Country
- CHRS United States
- AFCG United States
- Employees
- CHRS N/A
- AFCG N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- AFCG Real Estate Investment Trusts
- Sector
- CHRS Health Care
- AFCG Real Estate
- Exchange
- CHRS Nasdaq
- AFCG Nasdaq
- Market Cap
- CHRS 112.5M
- AFCG 113.0M
- IPO Year
- CHRS 2014
- AFCG 2021
- Fundamental
- Price
- CHRS $0.76
- AFCG $5.27
- Analyst Decision
- CHRS Strong Buy
- AFCG Buy
- Analyst Count
- CHRS 4
- AFCG 7
- Target Price
- CHRS $5.26
- AFCG $11.00
- AVG Volume (30 Days)
- CHRS 1.7M
- AFCG 129.0K
- Earning Date
- CHRS 05-12-2025
- AFCG 05-14-2025
- Dividend Yield
- CHRS N/A
- AFCG 25.07%
- EPS Growth
- CHRS N/A
- AFCG 84.02
- EPS
- CHRS N/A
- AFCG 0.96
- Revenue
- CHRS $272,251,000.00
- AFCG $41,036,509.00
- Revenue This Year
- CHRS N/A
- AFCG N/A
- Revenue Next Year
- CHRS N/A
- AFCG $23.25
- P/E Ratio
- CHRS N/A
- AFCG $5.51
- Revenue Growth
- CHRS 19.87
- AFCG N/A
- 52 Week Low
- CHRS $0.66
- AFCG $4.34
- 52 Week High
- CHRS $2.43
- AFCG $10.88
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- AFCG 43.59
- Support Level
- CHRS $0.71
- AFCG $5.01
- Resistance Level
- CHRS $1.06
- AFCG $5.87
- Average True Range (ATR)
- CHRS 0.08
- AFCG 0.26
- MACD
- CHRS -0.03
- AFCG 0.03
- Stochastic Oscillator
- CHRS 12.44
- AFCG 30.23
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.